Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors.
about
Hepatitis C virus/human T lymphotropic virus 1/2 co-infection: Regional burden and virological outcomes in people who inject drugsRoles of HTLV-1 basic Zip Factor (HBZ) in Viral Chronicity and Leukemic Transformation. Potential New Therapeutic Approaches to Prevent and Treat HTLV-1-Related DiseasesRecent Advances in BLV ResearchControversies in targeted therapy of adult T cell leukemia/lymphoma: ON target or OFF target effects?Differential role of PKC-induced c-Jun in HTLV-1 LTR activation by 12-O-tetradecanoylphorbol-13-acetate in different human T-cell lines.Characterization of simian T-cell leukemia virus type 1 in naturally infected Japanese macaques as a model of HTLV-1 infection.Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis.Susceptibility of primary HTLV-1 isolates from patients with HTLV-1-associated myelopathy to reverse transcriptase inhibitors.The transcription profile of Tax-3 is more similar to Tax-1 than Tax-2: insights into HTLV-3 potential leukemogenic properties.Chemoresistance to Valproate Treatment of Bovine Leukemia Virus-Infected Sheep; Identification of Improved HDAC Inhibitors.Massive depletion of bovine leukemia virus proviral clones located in genomic transcriptionally active sites during primary infection.Preventive and therapeutic strategies for bovine leukemia virus: lessons for HTLV.Characteristics of Adult T-Cell Leukemia/Lymphoma Patients with Long Survival: Prognostic Significance of Skin Lesions and Possible Beneficial Role of Valproic Acid.Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy/TrPA28γ is a novel corepressor of HTLV-1 replication and controls viral latency.Long Terminal Repeat Circular DNA as Markers of Active Viral Replication of Human T Lymphotropic Virus-1 in Vivo.Cellular Immune Responses against Simian T-Lymphotropic Virus Type 1 Target Tax in Infected Baboons.Immune Compromise in HIV-1/HTLV-1 Coinfection With Paradoxical Resolution of CD4 Lymphocytosis During Antiretroviral Therapy: A Case Report.Animal models on HTLV-1 and related viruses: what did we learn?"Antivirals" in the treatment of adult T cell leukaemia- lymphoma (ATLL).Therapeutic options for adult T-cell leukemia/lymphoma.Antiviral effect of raltegravir on HTLV-1 carriers.Molecular and Cellular Mechanism of Leukemogenesis of ATL: Emergent Evidence of a Significant Role for HBZ in HTLV-1-Induced Pathogenesis.Conference highlights of the 16th International Conference on Human Retrovirology: HTLV and related retroviruses, 26-30 June 2013, Montreal, Canada.[Human retrovirus HTLV-1: descriptive and molecular epidemiology, origin, evolution, diagnosis and associated diseases].HTLV-1, the Other Pathogenic Yet Neglected Human Retrovirus: From Transmission to Therapeutic Treatment.How to Control HTLV-1-Associated Diseases: Preventing de Novo Cellular Infection Using Antiviral Therapy.[Virological aspects of HTLV-1 infection and new therapeutical concepts].
P2860
Q26749788-46E180E8-03A4-4647-8719-62A10672843BQ26774352-1282CAD4-3470-47AD-86B6-44039B1542C9Q26776531-DE7E4233-CDD2-4569-B3E4-9936E02C33F6Q26852683-49A6D983-8D34-41BA-BE4F-CFCA793166F8Q31047557-F27CC935-4C3A-4EC6-9A72-DBE997FD7E70Q33590318-9CECC5D6-1CF5-41B0-B76A-0BF5199DD010Q33828002-389E64E0-E294-4BDA-AE14-9291FD97E078Q34223814-576E3453-D74C-4122-ABB9-049DA3C7F17DQ34387588-D167A0BD-83A3-4871-80BB-D08911637CABQ34533413-F0498809-E1FA-4E1F-8740-A9EC88E10C0BQ35008829-78B0A509-857B-42B0-8D2D-F52C2198FDDAQ35261563-C6EDB162-54EF-4625-9357-911BC2FD4D91Q35833900-E5A045C5-CCEB-4F58-BC24-98A4BAA94CC0Q36157642-18D91A77-0EEC-45E4-839F-2EC05AC1176CQ36584827-94AE5370-1C05-4CE3-BF52-B8678B0B8072Q36735681-A74AEE62-CA7E-41C3-8B95-907009786F22Q37069833-C6F32FA5-C29C-4269-A9AC-5A90B4F5C1B4Q37328362-EE100351-C16F-4D70-B6F9-9B5F48989622Q38050763-4123C5A6-2819-44D0-BAFB-DF3D999DD657Q38055062-78A2E6E2-4D5A-4D7B-B39C-D8B8676FBC2AQ38128790-DCDC0EDD-F504-450A-82B7-9E250D567476Q39533380-2FB89C81-723C-4F52-B430-42F2A7DEE7E2Q41724491-15F0C01D-44E9-4DA2-88A1-DDFD6F40337AQ42426735-624986CC-5260-4BD0-B46C-AE8EF20462B2Q46373938-4B9B3124-7B0F-42E8-A2AB-EAE45AF420B3Q47562043-EAABFDC3-9366-4342-AA5F-879C2F76DF68Q54246489-5433BAE8-7E3A-4020-8D69-499D14C28D3DQ55239254-C926C4CE-32B5-449A-B7A5-E964D5ED9B41
P2860
Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Highly active antiretroviral t ...... scriptase and HDAC inhibitors.
@en
type
label
Highly active antiretroviral t ...... scriptase and HDAC inhibitors.
@en
prefLabel
Highly active antiretroviral t ...... scriptase and HDAC inhibitors.
@en
P2093
P50
P1433
P1476
Highly active antiretroviral t ...... nscriptase and HDAC inhibitors
@en
P2093
Antoine Gessain
Antoine Moriceau
Eric Wattel
Guy Dubreuil
Mourad Mekaouche
Yves Plumelle
P304
P356
10.1182/BLOOD-2010-02-270751
P407
P50
P577
2010-06-29T00:00:00Z